Understand the source comparison
Best Peptides for Autism Research: Mechanism Comparison
Cerebrolysin Multi-target neurotrophic activation (BDNF, GDNF, NGF) via Trk receptors Moderate (requires IV administration for CNS effect) Restored dendritic spine density to 87% of wild-type in Shank3-deficient mice; normalized GABAergic transmission in hippo
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- Multi-target neurotrophic activation (BDNF, GDNF, NGF) via Trk receptors
- Moderate (requires IV administration for CNS effect)
- Restored dendritic spine density to 87% of wild-type in Shank3-deficient mice; normalized GABAergic transmission in hippocampal CA1 neurons
- Shank3, Fragile X, Rett syndrome models with documented BDNF pathway dysfunction
- Gold standard for neurotrophic intervention studies. Batch consistency is the primary technical limitation
- Dihexa
- HGF receptor potentiation; c-Met activation driving synaptogenesis
- High (crosses BBB at nanomolar concentrations, 7–10× more efficient than comparators)
- Increased synaptic density in cortical layer V pyramidal neurons by 40–60% within 72 hours; effects persist for weeks after single dose
- MET receptor dysfunction models, 16p11.2 deletion, any ASD variant with HGF/c-Met pathway disruption
- Strongest preclinical synaptogenesis data. Narrow therapeutic window requires precise dosing
- P21 (NAPVSIPQ)
- CREB phosphorylation and transcriptional activation of plasticity genes
- Moderate-High (effective via intranasal delivery, bypasses BBB via olfactory pathway)
- Increased hippocampal CREB phosphorylation by 340%; improved novel object recognition by 55% vs controls
- Fragile X, Rett, Angelman syndrome. Any condition with impaired CREB-mediated transcription
- Excellent for memory and plasticity endpoints. Dosing above 1 mg/kg triggers compensatory downregulation
- Thymalin
- Microglial modulation; shifts M1 (pro-inflammatory) to M2 (anti-inflammatory) phenotype; suppresses IL-6, TNF-alpha
- Low (immune-modulating effects are systemic and CNS-penetrant via cytokine signaling)
- Reduced prefrontal cortex microglial density by 38% in MIA offspring; normalized social interaction deficits
- Maternal immune activation (MIA) models, any neuroinflammatory ASD subtype
- Best choice for immune-mediated autism research. Requires endotoxin-free preparation to avoid confounds
- MK-677 (Ibutamoren)
- Growth hormone secretagogue; elevates IGF-1, which regulates neuronal survival and synaptic development
- High (orally bioavailable, sustained GH/IGF-1 elevation without injection)
- Low IGF-1 correlates with autism severity; IGF-1 administration improves social deficits in Rett syndrome mice
- Rett syndrome, low-IGF-1 ASD subtypes, chronic dosing protocols requiring stable pharmacokinetics
- Valuable for IGF-1 pathway studies. Oral bioavailability simplifies chronic dosing vs injectable GH